BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guida M, Bartolomeo N, De Risi I, Fucci L, Armenio A, Filannino R, Ruggieri E, Macina F, Traversa M, Nardone A, Figliuolo F, De Luca F, Mele F, Tommasi S, Strippoli S. The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma. Cancers (Basel) 2019;11:E1559. [PMID: 31615127 DOI: 10.3390/cancers11101559] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Quaresmini D, Di Lauro A, Fucci L, Strippoli S, De Risi I, Sciacovelli AM, Albano A, Achille G, Montepara M, Russo S, Tassone G, Guida M. Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp. Front Oncol 2021;11:742666. [PMID: 34604086 DOI: 10.3389/fonc.2021.742666] [Reference Citation Analysis]
2 De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int 2021. [PMID: 34228889 DOI: 10.1111/bju.15541] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Guida M, Bartolomeo N, Quaglino P, Madonna G, Pigozzo J, Di Giacomo AM, Minisini AM, Tucci M, Spagnolo F, Occelli M, Ridolfi L, Queirolo P, De Risi I, Quaresmini D, Gambale E, Chiaron Sileni V, Ascierto PA, Stigliano L, Strippoli S, On Behalf Of The Italian Melanoma Intergroup Imi Study. No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. Cancers (Basel) 2021;13:475. [PMID: 33530579 DOI: 10.3390/cancers13030475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
4 Porcelli L, Guida M, De Summa S, Di Fonte R, De Risi I, Garofoli M, Caputo M, Negri A, Strippoli S, Serratì S, Azzariti A. uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients. J Immunother Cancer 2021;9:e002372. [PMID: 33972390 DOI: 10.1136/jitc-2021-002372] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Strippoli S, Fanizzi A, Negri A, Quaresmini D, Nardone A, Armenio A, Sciacovelli AM, Massafra R, De Risi I, De Tullio G, Albano A, Guida M. Examining the Relationship between Circulating CD4- CD8- Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy-Looking for Biomarkers and Therapeutic Targets in Metastatic Melanoma. Cells 2021;10:406. [PMID: 33669266 DOI: 10.3390/cells10020406] [Reference Citation Analysis]
6 Stagno A, Vari S, Annovazzi A, Anelli V, Russillo M, Cognetti F, Ferraresi V. Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting? Front Oncol 2021;11:645008. [PMID: 34136385 DOI: 10.3389/fonc.2021.645008] [Reference Citation Analysis]
7 Guida M, Bartolomeo N, Quaresmini D, Quaglino P, Madonna G, Pigozzo J, Di Giacomo AM, Minisini AM, Tucci M, Spagnolo F, Occelli M, Ridolfi L, Queirolo P, De Risi I, Valente M, Sciacovelli AM, Chiarion Sileni V, Ascierto PA, Stigliano L, Strippoli S. Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. J Transl Med 2022;20:159. [PMID: 35382857 DOI: 10.1186/s12967-022-03359-x] [Reference Citation Analysis]
8 Xu Y, Li H, Fan Y. Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer. Front Oncol 2021;11:642883. [PMID: 33747966 DOI: 10.3389/fonc.2021.642883] [Reference Citation Analysis]
9 Mangin MA, Boespflug A, Maucort Boulch D, Vacheron CH, Carpentier I, Thomas L, Dalle S. Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma. Cancer Med 2021;10:3155-64. [PMID: 33932099 DOI: 10.1002/cam4.3760] [Reference Citation Analysis]
10 Guida M, Strippoli S, Maule M, Quaglino P, Ramondetta A, Chiaron Sileni V, Antonini Cappellini G, Queirolo P, Ridolfi L, Del Vecchio M, Cocorocchio E, Di Giacomo AM, Festino L, Merelli B, Occelli M, Brugnara S, Minisini A, Sava S, Tommasi S, De Summa S; Italian Melanoma Intergroup. Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. ESMO Open 2021;6:100064. [PMID: 33711672 DOI: 10.1016/j.esmoop.2021.100064] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Rheinheimer S, Heussel CP, Mayer P, Gaissmaier L, Bozorgmehr F, Winter H, Herth FJ, Muley T, Liersch S, Bischoff H, Kriegsmann M, El Shafie RA, Stenzinger A, Thomas M, Kauczor HU, Christopoulos P. Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors. Cancers (Basel) 2020;12:E1046. [PMID: 32340408 DOI: 10.3390/cancers12041046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
12 Rauwerdink DJW, Molina G, Frederick DT, Sharova T, van der Hage J, Cohen S, Boland GM. Mixed Response to Immunotherapy in Patients with Metastatic Melanoma. Ann Surg Oncol 2020;27:3488-97. [PMID: 32472413 DOI: 10.1245/s10434-020-08657-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
13 Alomran R, White M, Bruce M, Bressel M, Roache S, Karroum L, Hanna GG, Siva S, Goel S, David S. Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR). BMC Cancer 2021;21:303. [PMID: 33757458 DOI: 10.1186/s12885-021-08042-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]